EVOTEC SE INH
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Carsten Mainitz on October 7th, 2026 | 08:40 CEST
Spot the Next Stock Catalyst Early: Key Milestones for Lahontan Gold, Evotec and Deutz
Get in before the stock takes off! The key is to identify the trigger for the next share-price move early enough. Lahontan Gold is working to restart a historic gold mine in Nevada and recently made an attractive acquisition. Biotech company Evotec is fighting to turn its operations around and rebuild investor confidence. Deutz is expanding its industrial business into energy and defense, taking the company into new dimensions of growth. What does this mean for investors? Where are the most compelling opportunities for stock pickers?
Read
Commented by Matthias Schomber on October 1st, 2026 | 07:55 CEST
Evotec, DroneShield and Power Metallic Mines: Turnaround Opportunities, Defence Boom and Commodities Hidden Gem
The stock market can be a madhouse at the best of times—and right now, some developments seem to defy all logic. Yet markets are rarely driven by fundamentals alone. Greed, fear and shifting investor sentiment can send stocks in directions that appear difficult to explain from a purely rational perspective. While the cards are being reshuffled at Evotec's modern laboratories following a management shakeup, DroneShield is looking to benefit from the new defence boom in the skies. In Canada, Power Metallic Mines sits on a vast polymetallic deposit. Each of the three stocks has its own technical chart setup. We examine the hard facts, look at margins and balance sheets, and assess the real opportunities. Which of these three stocks offers significant turnaround potential, and where do risks still loom? Read on to find out.
Read
Commented by Fabian Lorenz on September 22nd, 2026 | 07:45 CEST
Analysts See Multibagger Potential: Nordex, Evotec and Aspermont
Analysts see multibagger potential in Aspermont's stock. The Australian company appears to be making good progress in its transformation from a specialist publisher into a scalable provider of data and analytics for the global resources industry. The stock has yet to take off. Its 2028 P/E ratio is below 10. Nordex is no longer a bargain. Analysts see further growth opportunities, but the stock has already priced in much of that potential. Nevertheless, analysts recommend buying the shares. The US business is becoming increasingly important. Buying Evotec shares is not an obvious choice right now. The stock has fallen below EUR 3, while positive company news is being ignored by the market. Could this perhaps be an opportunity?
Read
Commented by Armin Schulz on September 21st, 2026 | 07:30 CEST
Novo Nordisk, BioNxt Solutions, Evotec: When Injections Become Pills, The Cash Starts Rolling In
The daily injection has had its day. For a long time, taking biologics in pill form was considered a pipe dream, but as of this year, it is becoming a billion-dollar business. On September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicines worth up to USD 1.4 billion to make injections available orally. In February, the Danish company secured a partnership with Vivtex worth up to USD 2.1 billion. Whoever can deliver peptides through the stomach could see the industry come knocking. We are taking a closer look at Novo Nordisk, BioNxt Solutions and Evotec, which cover the entire spectrum of this trend—from acquisitions to technology to development.
Read
Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST
New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention
Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?
Read
Commented by Fabian Lorenz on September 9th, 2026 | 07:00 CEST
Evotec Under Pressure! Analysts See Upside Potential - News From MustGrow and Bayer
Created and Published on Behalf of MustGrow Biologics Corp.
Alarm bells are ringing at Evotec. The share price is at risk of slipping below the EUR 3 mark. Even at this seemingly low price level, analysts are notably reluctant to issue "Buy" recommendations. Evotec has, however, announced a research collaboration to develop new T-cell-activating therapeutic approaches for solid tumors. MustGrow's story is now gaining noticeable momentum. The Canadian AgTech company reached profitability in the first half of the year and expects revenue to increase in the second half. In addition, the first milestone payment from Bayer under their licensing agreement has been received. Further payments running into the millions could follow in the coming years and exceed MustGrow's current market capitalization. Analysts see potential for significant upside. Bayer itself has announced an intensive phase of new product launches for its Crop Science division. Analysts recommend buying the stock.
Read
Commented by André Will-Laudien on September 8th, 2026 | 09:40 CEST
Biotech: Time to Bet on the Rebound! Evotec and BioNxt in the Takeover Spotlight, Bayer and BioNTech Flush with Cash
After a long dry spell, the biotech sector is on the cusp of a spectacular turnaround, offering bold investors the potential for significant returns. Many innovative biotech stocks are trading well below their all-time highs, yet almost unnoticed, the next major rally is already taking shape behind the scenes. The huge cash reserves of industry giants Bayer and BioNTech are currently fueling takeover speculation across the sector. This colossal capital, running into the billions, is desperately seeking new growth drivers, suddenly putting smaller players on the radar of potential acquirers. At the very top of the hunters' watchlist are the hard-hit Evotec and the disruptive newcomer BioNxt. Both companies boast top-class technology platforms, which, at current levels, almost seem like an exclusive clearance sale. Investors who keep their eyes open and position themselves strategically for the major rebound could get ahead of the looming wave of consolidation. The conditions for an explosive catch-up rally have rarely been this favorable.
Read
Commented by Fabian Lorenz on September 1st, 2026 | 07:45 CEST
Potential Moderna-Style Share Surge? Takeover Candidates Evotec, Valneva and Vidac Pharma in Focus — Analysts Bullish
Moderna has shaken up the biotech market with its breakthrough in the fight against skin cancer. Partner Merck has received somewhat less attention in the coverage, despite preparing for the eventual patent expiration of one of its blockbuster drugs. Other pharmaceutical companies will also need to replenish their pipelines in the coming years. As a result, the takeover merry-go-round is likely to pick up speed again, potentially electrifying investors. One hot candidate is Vidac Pharma. Recruitment for its Phase 2B trial into high-risk actinic keratosis, a precancerous skin condition, has been completed. The results could provide a catalyst for the stock. Valneva's share price has recently risen sharply. Could its partner Pfizer eventually make a move? Analysts are recommending the stock. And what about perennial takeover candidate Evotec? Shareholders and potential buyers are currently giving the share a wide berth. Yet there is a "Buy" recommendation on the table.
Read